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Background: Type 2 diabetes mellitus (DM) is associated with the microvascular and 
macrovascular complication. Metformin and sulphonylurea (glimepiride and glibenclamide) 
combination is widely used for the treatment of type 2 DM. This study aimed to examine the 
difference of Metformin/Glimepiride and Metformin/Glibenclamide administrations in reducing 
HbA1C among type 2 DM patients. 
Subjects and Method: This was a systematic review and meta-analysis according to PRISMA 
guideline with PICO construction using MeSH and text-word. 214 article were identified from 
PubMed, Cochrane, other source databases. Two articles with 183 type 2 DM  patients were 
selected for this study. 
Results: No significant difference on HbA1C level, fasting plasma glucose, and hypoglycemia 
adverse events between glimepiride/metformin and glibenclamide/metformin combinations. 
However, glimepiride/metformin combination demonstrated lower HbA1C (-0.11; 95% CI= -0.41 to 
0.18; p= 0.450) and lower hypoglycemia adverse events (OR= 0.52; 95% CI= -1.02 to 3.05; p= 
0.450), while glibenclamide/metformin combination demonstrated lower fasting plasma glucose 
concentration (1.01; 95% CI= -1.02 to 3.05; p= 0.450). 
Conclusion: Glimepiride/metformin combination is preferable in HbA1C lowering and 
hypoglycemia risk than glibenclamide/metformin combination. 
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The disease burden related to diabetes is 
high and global prevalence in 2035 is 
expected to rise to 592 million people in the 
whole world (Forouhi dan Wareham, 2014). 
HbA1C and fasting plasma glucose concen-
tration maintaining in the target range are 
important to prevent microvascular (retino-
pathy, nephropathy, and neuropathy) and 
macrovascular (cardiovascular disease) 
complication (Chawla et al., 2016; Juarez et 
al., 2014). Metformin, glimepiride, and 
glibenclamide are an example of type 2 
diabetes mellitus drugs. Sulfonylurea-
biguanide combination is common to use 
and recommended for the treatment of type 
2 DM in dual therapy (Aamir et al., 2015; 
Ridle et al, 2018). A Comprehensive review 
of comparison of the combinations is still 
unknown. The objective of the study is to 
compare efficacy (HbA1C and fasting 
plasma glucose) and Adverse event 
(Hypoglycemia).  
 
SUBJECTS AND METHOD 
1. Study design 
The systematic review and meta-analysis 
are according to the Preferred Reporting 
Items for Systematic Reviews and Meta-
Analyses guidelines (PRISMA) (Moher et 
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al, 2009). The search strategy includes 
articles indexed in PubMed, Cochrane data-
base and other resources (worldwide web-
site) with study selection using Problem, 
Intervention, and Comparison (PICO cons-
tructed) with Medical Subject Heading 
(MeSH) and keywords ―Diabetes Mellitus, 
Type 2‖, ―Metformin‖, ―Glyburide‖, ―Glime-
piride‖, ―Glibenclamide‖. 
The studies need to fulfill the follow-
ing inclusion criteria: (1) Glimepiride/ Met-
formin as intervention drugs, Glibencla-
mide/Metformin as a comparator (2) Type 
2 Diabetes Mellitus patients, (3) rando-
mized controlled trials study design, (4) 
HbA1C, Fasting Plasma Glucose as an out-
come, Hypoglycemia as an adverse event 
(5) original articles, and (6) study published 
in the English language publications. The 
data were extracted from each publication 
involved source of study (year), study 
design, sample size (number of subjects), 
duration of treatment, outcome (HbA1C, 
Fasting Plasma Glucose, Hypoglycemia 
adverse event), and article quality. 
2. Data analysis 
The Data were analyzed using RevMan 5.3. 
Data were expressed as standard mean 
difference (HbA1C and Fasting Plasma 
Glucose) or Odds Ratio (Hypoglycemia 
adverse event) using a 95% confidence 
interval. The P value < 0.05 was defined as 
statistically significant for all outcomes. 
 
RESULTS 
The Initial search identified 214 articles, 
which 123 articles from Cochrane, 90 arti-
cles from Pubmed, and 1 article from other 
sources (Figure 1). 210 articles are excluded 
unlikely to be relevant based on the title 
and abstract screening. Four articles are 
included for the full review article.  
Two article is excluded after the full 
review due to the 1). Glibenclamide is not a 
comparator in combination with metform-
in, 2). Glimepiride is not an interventions 
drugs in combination metformin. Two arti-
cles are included for qualitative and quan-
titative analysis. The article's method is 
randomized controlled trials (1 article are 
open-label; 1 article double-blind and 
multicenter) and 183 patients are involved 
in the study with 3 patients are not 
completed the study. 
1. HbA1C 
Glimepiride/metformin combination did 
not show significant difference of HbA1C 
reduction compared with glibenclamide/ 
metformin combination (-0.11; 95% CI= -
0.41 to 0.18; p= 0.45). Moreover, not found 
statistical heterogeneity in this trials (p= 
0.43). However, glimepiride/metformin 
combination showed lower HbA1C concen-
tration than glibenclamide/metformin 
combination. 
2. Fasting Plasma Glucose 
Fasting plasma glucose demonstrated the 
same results with HbA1C parameter. No 
significant difference were observed bet-
ween glimepiride/metformin and gliben-
clamide/ metformin combination in fasting 
plasma glucose concentration (1.01; 95% 
CI= -1.02 to 3.05; p= 0.45). However, gli-
benclamide/ metformin combination show-
ed lower fasting plasma glucose concentra-
tion than glimepiride/metformin combina-
tion. 
3. Hypoglycemia Adverse Events 
Hypoglycemia is a serious problem in type 
2 diabetes mellitus medication. No signifi-
cant difference were observed of hypoglyce-
mia adverse events between glimepiride/ 
metformin and glibenclamide/metformin 
group (OR= 0.52; 95% CI= -1.02 to 3.05; 
p= 0.450). However, glimepiride/ metfor-
min combination showed lower hypoglyce-
mia adverse events compared with gliben-
clamide/metformin combinations. 
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Figure 4. Hypoglycemia Adverse Events  
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DISCUSSION 
Metformin is the first line of choice for 
Type 2 Diabetes Mellitus, if does not 
achieve the HbA1C goal over 3 months, add 
an additional of other antihyperglycemics 
(American Diabetes Association, 2018). 
Glibenclamide and Glimepiride widely used 
as a second line therapy in combination 
with metformin (Rani et al., 2014). HbA1C 
is an important parameter to achieve in 
type 2 diabetes mellitus patients and 
associated with all-cause mortality, while 
hypoglycemia is a common adverse reaction 
and life-threatening associated (American 
Diabetes Association, 2018; Arnold and 
Wang, 2014). Studies have shown that 
incidence rates of hypoglycemia in sulpho-
nylurea users range from 0.2-1.8 per 100 
people (without renal impairment) (Van 
Dalem, 2016). Therefore, achieved HbA1C 
goal and minimize hypoglycemia risk is an 
important goal in type 2 diabetes mellitus 
medications. 
No significant difference is observed 
on HbA1C, fasting plasma glucose, and 
hypoglycemia adverse events between gli-
mepiride/metformin and glibenclamide/ 
metformin combination. However, glime-
piride/ metformin combination demons-
trated lower HbA1C and hypoglycemia 
adverse events, while glibenclamide/ met-
formin combination demonstrated lower 
fasting plasma glucose concentration. 
Glimepiride and glibenclamide are in 
the same class of sulphonylurea group. 
However, there is difference engagement 
for the mechanism of action between 
glimepiride and glibenclamide. Glimepiride 
molecular study demonstrated interaction 
with lipid rafts, DIGs, at the plasma mem-
brane of adipose and muscle cells induces 
the insulin-mimetic activity via the activa-
tion of a glycosylphosphatidylinositol-spe-
cific phospholipase, redistribution of sig-
naling components and positive cross-talk 
downstream to the insulin signaling cas-
cade and interference with additional mole-
cular mechanisms in extrapancreatic cells 
(e.g. regulation of adipocytokine release 
from and differentiation of adipocytes), 
relying on or independent of SUR and 
DIGs, contributes to the insulin-sensitizing 
activity of glimepiride (Muller, 2005).The 
molecular characterization between glime-
piride and glibenclamide showed kinetic, 
steady state and competitive binding of 
glimepiride is 3- to 4-fold lower binding 
affinity to isolated beta-cell membranes and 
intact beta-cells compared to glibencla-
mide, while for photoaffinity labelling of 
beta-cells membrane protein showed 65-
kDA binding protein for glimepiride and 
140-kDA binding protein for glibenclamide. 
Moreover, glimepiride showed 3- to 4-fold 
lower depolarization activity than glibencla-
mide (Kramer et al., 1996; Hu et al.,2000). 
The low risk hypoglycemia adverse events 
may be due to the lowest affinity, binding 
and depolarization activity of glimepiride 
than glibenclamide. 
Based on the results of this study, it 
can conclude that glimepiride/metformin 
combination is preferable in HbA1C lower-
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